Moderna’s Investigational Zika Vaccine Is Granted FDA Fast Track Designation

From Moderna 
From the press release we learned that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Moderna (MRNA) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.

This is good news for

This content is for paid subscribers.
Please click here to subscribe or here to log in.